Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension

Medical Care

Volumn 51, Issue 10, 2013, Pages 879-887

  An, Jaejin ^a,b   Nichol, Michael B ^b,c  

^a Pharmacy Analytical Service   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Outcomes Research (ISPOR) 16th Annual International Meeting   (United States)

Author keywords

adherence; instrumental variables; multiple chronic conditions

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN SENSITIZING AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONFERENCE PAPER; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INSTRUMENTAL VARIABLE ANALYSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CALIFORNIA; CAUSALITY; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 84884821233     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31829fa8ed     Document Type: Conference Paper

References (32)

1. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
2. Paez KA, Zhao L, Hwang W. Rising out-of-pocket spending for chronic conditions: a ten-year trend. Health Aff. 2009;28:15-25.
3. Gre- S, Baan CA, Clanan M, et al. Co-ordination and management of chronic conditions in Europe: the role of primary care-position paper of the European forum for primary care. Qual Prim Care. 2009;17:75-86.
4. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403-418.
5. ADVANCE Collaborative Group. Patel A, MacMahon S. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
6. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725-731.
7. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62:76-87.
8. Chewning B. The healthy adherer and the placebo effect. BMJ. 2006;333:18-19.
9. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45:521-528.
10. Imbens G, Angrist J. Identification and estimation of local average treatment effects. Econometrica. 1994;62:467-476.
11. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275.
12. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat. 2007;3:14.
13. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003;115:715-720.
14. Schneeweiss S, Glynn RJ, Avorn J, et al. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005;58:98-102.
15. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3-12.
16. Zeng F, An JJ, Scully R, et al. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13:846-852.
17. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
18. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-430.
19. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS BMJ. 1998;317:703-713.
21. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
22. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
23. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
24. American Diabetes Association. Standards of medical care in diabetes- 2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
25. Hosmer DW, Lemeshow S. Applied Logistic Regression (2nd ed). New York: John Wiley & Sons Inc.; 2000;373.
26. Stock JH, Wright JH, Yogo MA. Survey of weak instruments and weak identification in Generalized Method of Moments. J Am Stat Assoc. 2002;20:518-529.
27. Hansen LP. Large sample properties of generalized method of moments estimators. Econometrica. 1982;50:1029-1054.
28. Baum CF. An Introduction to Modern Econometrics Using Stata. College Station, TX: Stata Press; 2006.
29. Reach G. Role of habit in adherence to medical treatment. Diabet Med. 2005;22:415-420.
30. Bolman C, Arwert TG, Vo?llink T. Adherence to prophylactic asthma medication: habit strength and cognitions. Heart Lung. 2011;40:63-75.
31. Atreja A, Bellam N, Levy S. Strategies to enhance patient adherence: making it simple. Medacapt Gen Med. 2005;7:4.
32. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331-342.